PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.43 - 1.45
1.18 - 2.36
880.0K / 1.73M (Avg.)
-18.00 | -0.08
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
75.69%
Revenue growth 1.25-1.5x 1113.HK's 54.29%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
187.44%
Gross profit growth above 1.5x 1113.HK's 35.55%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
No Data
No Data available this quarter, please select a different quarter.
1.81%
Operating income growth under 50% of 1113.HK's 39.92%. Michael Burry would be concerned about deeper cost or sales issues.
-4.44%
Negative net income growth while 1113.HK stands at 25.60%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.00%
Slight or no buybacks while 1113.HK is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.07%
Negative OCF growth while 1113.HK is at 33.43%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-58.48%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-83.82%
Negative 10Y revenue/share CAGR while 1113.HK stands at 340.14%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
51804.85%
5Y revenue/share CAGR above 1.5x 1113.HK's 340.14%. David Dodd would look for consistent product or market expansions fueling outperformance.
2575.51%
3Y revenue/share CAGR above 1.5x 1113.HK's 396.57%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-146.22%
Negative 10Y OCF/share CAGR while 1113.HK stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-138.24%
Negative 5Y OCF/share CAGR while 1113.HK is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
31.75%
3Y OCF/share CAGR under 50% of 1113.HK's 1087.23%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-804.83%
Negative 10Y net income/share CAGR while 1113.HK is at 27.26%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-742.20%
Negative 5Y net income/share CAGR while 1113.HK is 27.26%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-307.69%
Negative 3Y CAGR while 1113.HK is 50.54%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
176.96%
Below 50% of 1113.HK's 1229.15%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
6.27%
Below 50% of 1113.HK's 1117.68%. Michael Burry suspects a serious short-term disadvantage in building book value.
-100.00%
Cut dividends over 10 years while 1113.HK stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-100.00%
Negative 5Y dividend/share CAGR while 1113.HK stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-100.00%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-100.00%
Firm’s AR is declining while 1113.HK shows 32.41%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
36.39%
We show growth while 1113.HK is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-2.81%
Negative asset growth while 1113.HK invests at 6.57%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-6.06%
We have a declining book value while 1113.HK shows 1.80%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
444.00%
Debt growth far above 1113.HK's 22.65%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.